mTOR and rapamycin: a review that leaves the human question open
2026-05-13 · Reviewed 2026-10-07
A 2026 GeroScience review by Dudley W. Lamming follows rapamycin into geroscience and says the human healthspan question is unresolved.
The article was published on 13 May 2026. This page uses the abstract. It does not provide a dose, a schedule, or a reason to take rapamycin.
Biological mechanism
The abstract identifies rapamycin as an inhibitor of mTOR, a nutrient-sensing kinase, first used as an immunosuppressant.
What was reported
The author frames rapamycin as a widely studied pharmacological geroprotector and says model-organism work has reported effects on lifespan and on organ systems.
Organism
The abstract covers model organisms and also refers to human trials. This page does not invent which trials or how many people were enrolled.
Main results
The abstract says side effects may limit translation and that it is still unresolved whether rapamycin, or a similar mTOR inhibitor, can extend human healthspan and lifespan.
Limitations
A review is not a new clinical result. Off-label use mentioned as a social fact in the abstract is not an endorsement.
Known risks
The abstract points to side effects and to the drug’s history as an immunosuppressant. This site does not list a personal protocol.
What is still unproven
Whether any mTOR inhibitor extends human life remains unanswered here.
Scientific sources
- Bench to bedside: is rapamycin headed for the docTOR? Lamming DW. GeroScience, 2026-05-13. DOI 10.1007/s11357-026-02306-8
Educational information, not medical advice. This site does not publish experimental protocols for personal use and does not recommend genetic therapies, senolytics, or experimental drugs.